Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors
| Study Name | |
| Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors | |
| ClinicalTrials.gov Identifier (if applicable) | |
| https://www.clinicaltrials.gov/ct2/show/NCT02746081?term=IDH1&rank=6 | |
| Study Center | |
| Institution Name | |
| USC Norris Comprehensive Cancer Center | |
| Institution Address | |
| 1441 Eastlake Ave | |
| City | |
| Los Angeles | |
| State | |
| California | |
| Zip Code | |
| 90089 | |
| Phone | |
| (323) 865-3967 | |
| Website | |
| http://www.uscnorris.com | |
| Study Contacts | |
| Principal Investigator | |
| Heinz Josef Lenz | |
| P.I. Phone | |
| (323) 865-3967 | |
| P.I. Email | |
| lenz@usc.edu | |
| Study Coordinator | |
| Jubilee Acap | |
| Study Coordinator Phone | |
| (323) 865-3900 | |
| Study Coordinator Email | |
| jubilee.acap@med.usc.edu | |
| OVERVIEW – in layman’s terms (150 words max) | |
| An Open-label, Non-Randomized (the participants are not assigned by chance to different treatment groups), Multi-center, Phase I Study. Phase II Dose of the Orally taken Mutant IDH Inhibitor BAY 1436032. Cohorts will consist of patients representing the following IDH1-R132X-mutant intrahepatic cholangioncarcinoma, glioblastoma/ anaplastic glioma |
|
| Enrollment | |
| open | |
| Study Start Date | |
| 12/01/2016 | |
| Estimated Completion Date | |
| 01/31/2018 | |
| Inclusion Criteria – Patients Must: | |
|
|
| REQUIRED TESTS PRIOR TO BEGINNING STUDY TREATMENT – in layman’s terms | |
|
|
